Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GLYC Glycomimetics Inc
- Stocks
- Healthcare
- NASDAQ: GLYC
Price (delayed)
$0.21
Market cap
$13.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.46
Enterprise value
$7.94M
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate
Highlights
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
Glycomimetics's net income has increased by 22% QoQ and by 21% YoY
GLYC's quick ratio has shrunk by 64% YoY but it is up by 16% QoQ
The gross profit has dropped by 100% year-on-year
Glycomimetics's revenue has plunged by 100% YoY
Key stats
What are the main financial stats of GLYC
Market
Valuations
Earnings
Shares outstanding
64.53M
Market cap
$13.55M
Enterprise value
$7.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.01
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.32M
Net income
-$29.49M
EBIT
-$29.49M
EBITDA
-$29.23M
Free cash flow
-$25.67M
Per share
Balance sheet
Liquidity
EPS
-$0.46
EPS diluted
-$0.46
Free cash flow per share
-$0.4
Book value per share
$0.05
Revenue per share
$0
TBVPS
$0.09
Total assets
$5.99M
Total liabilities
$2.62M
Debt
$0
Equity
$3.38M
Working capital
$3.38M
Debt to equity
0
Current ratio
2.29
Quick ratio
2.15
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-206.2%
Return on equity
-293.9%
Return on invested capital
N/A
Return on capital employed
-873.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLYC stock price
How has the Glycomimetics stock price performed over time
Intraday
0.48%
1 week
-3.76%
1 month
-19.72%
1 year
-28.55%
YTD
-15.66%
QTD
0%
Financial performance
How have Glycomimetics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.32M
Net income
-$29.49M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
Glycomimetics's revenue has plunged by 100% YoY
Glycomimetics's net income has increased by 22% QoQ and by 21% YoY
Glycomimetics's operating income has increased by 22% from the previous quarter and by 21% YoY
Price vs fundamentals
How does GLYC's price correlate with its fundamentals
Growth
What is Glycomimetics's growth rate over time
Valuation
What is Glycomimetics stock price valuation
P/E
N/A
P/B
4.01
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 22% QoQ and by 21% YoY
GLYC's price to book (P/B) is 111% higher than its 5-year quarterly average of 1.9 and 82% higher than its last 4 quarters average of 2.2
Glycomimetics's equity has plunged by 88% YoY and by 36% from the previous quarter
Glycomimetics's revenue has plunged by 100% YoY
Efficiency
How efficient is Glycomimetics business performance
Glycomimetics's return on assets has shrunk by 169% YoY and by 16% QoQ
The ROE has contracted by 27% from the previous quarter
Dividends
What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLYC.
Financial health
How did Glycomimetics financials performed over time
The total assets is 129% more than the total liabilities
The total assets has plunged by 82% YoY and by 46% from the previous quarter
Glycomimetics's current ratio has shrunk by 64% YoY but it has increased by 19% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
GLYC's debt to equity has dropped by 100% since the previous quarter and by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.